WO2021255979A1 - Composition anti-obésité et composition pour administration orale - Google Patents

Composition anti-obésité et composition pour administration orale Download PDF

Info

Publication number
WO2021255979A1
WO2021255979A1 PCT/JP2021/003384 JP2021003384W WO2021255979A1 WO 2021255979 A1 WO2021255979 A1 WO 2021255979A1 JP 2021003384 W JP2021003384 W JP 2021003384W WO 2021255979 A1 WO2021255979 A1 WO 2021255979A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
promoting
tectrigenins
pinitol
fat
Prior art date
Application number
PCT/JP2021/003384
Other languages
English (en)
Japanese (ja)
Inventor
千絵 中島
琢海 森川
智康 神谷
Original Assignee
株式会社東洋新薬
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社東洋新薬 filed Critical 株式会社東洋新薬
Priority to US17/800,584 priority Critical patent/US20230123101A1/en
Priority to JP2021508004A priority patent/JP6903367B1/ja
Priority to CN202180012480.1A priority patent/CN115052591A/zh
Priority to KR1020227026940A priority patent/KR20230023604A/ko
Publication of WO2021255979A1 publication Critical patent/WO2021255979A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to each composition used for anti-obesity, body fat reduction, fat metabolism promotion, fat burning promotion, heat production promotion, energy consumption promotion, and oral use.
  • the present invention also relates to the use of tectrigenins and pinitol in the production of functional foods for improving obesity, reducing body fat, promoting fat metabolism, promoting fat burning, promoting heat production or promoting energy consumption.
  • the present invention also relates to a method for improving obesity, reducing body fat, promoting fat metabolism, promoting fat burning, promoting heat production or promoting energy consumption, using a composition containing tectrigenins and pinitol.
  • Obesity is closely related to fat consumption in the body, and fat consumption specifically consists of the following mechanisms.
  • hormone-sensitive lipase which is a lipolytic enzyme
  • white adipocytes distributed subcutaneously and visceral
  • triglycerides neutral fat stored in white adipocytes are decomposed. It becomes glycerol and free fatty acids and is released into the blood. Free fatty acids released into the blood are taken up by the mitochondria of brown adipocytes distributed near the clavicle, around the chest, shoulders, etc., in addition to the liver and muscles, and are consumed as heat.
  • UCP1 and PGC1 ⁇ are known as one of the candidate molecules involved in the autonomous regulation of energy consumption.
  • UCP has the function of uncoupling the oxidative phosphorylation reaction in the inner mitochondrial membrane and dissipating energy as heat.
  • UCP1 For UCP1 of the most typical brown cell fat, 1. UCP1 function is impaired in obese animals. 2. UCP1 is increased in animals that do not become obese even if they eat a lot. It is known that mice in which UCP1 gene expression is artificially reduced are obese and mice with high expression are thin.
  • PGC1 ⁇ is known to have an action of mediating the activation of UCP1 by stimulation of ⁇ -adrenergic receptor of brown adipocytes and promoting the proliferation of mitochondria (Non-Patent Document 1). Therefore, since an anti-obesity effect can be expected by activating UCP1 and PGC1 ⁇ , drugs and foods having excellent activation of UCP1 and PGC1 ⁇ have been sought.
  • Patent Document 1 various anti-obesity agents including Patent Document 1 have been conventionally known as having the problem of reducing white adipose tissue such as subcutaneous fat.
  • the action of consuming energy such as fatty acids in brown adipocytes to generate heat (hereinafter also referred to as "energy consuming action”) is important for lipid metabolism, but if this action can be activated, it will be better in the body. It can be expected that a large amount of fat is converted into heat and an anti-obesity effect can be obtained more effectively.
  • promotion of energy-consuming action in brown adipocytes has not been investigated. Further, as examined by the present inventor, it cannot be said that the conventional anti-obesity agents, which are said to be able to reduce white adipose tissue by themselves, are sufficient in promoting the energy-consuming action performed in brown adipocytes. I found out.
  • the present inventors have diligently investigated the composition of a composition capable of promoting the energy-consuming action in brown adipocytes by investigating the gene expression of proteins such as PGC1 ⁇ and UCP1 involved in the energy-consuming action in brown adipocytes. As a result, it was found that the expression of these genes can be surprisingly promoted by combining specific components, and the above-mentioned excellent effect of promoting energy consumption can be obtained.
  • the present invention is based on the above findings, and provides an anti-obesity composition containing tectrigenins and pinitol.
  • the present invention provides a composition for reducing body fat or promoting fat metabolism containing tectrigenins and pinitol.
  • the present invention provides a composition for promoting fat burning, promoting heat production, or promoting energy consumption, which contains tectrigenins and pinitol.
  • the present invention also provides an oral composition containing tectrigenins and pinitol.
  • the present invention also provides the use of tectrigenins and pinitol in the production of functional foods for improving obesity, reducing body fat, promoting fat metabolism, promoting fat burning, promoting heat production or promoting energy consumption. be.
  • the present invention also provides a method for improving obesity, reducing body fat, promoting fat metabolism, promoting fat burning, promoting heat production or promoting energy consumption, using a composition containing tectrigenins and pinitol. ..
  • a useful oral composition containing a composition containing tectrigenins and pinitol, and in particular, gene expression of proteins such as PGC1 ⁇ and UCP1 involved in energy consumption in brown adipose cells. It can be promoted and has the effect of promoting energy consumption in brown adipose cells, and is an effective anti-obesity composition, body fat reducing composition, adipose metabolism promoting composition, fat burning promoting composition, and thermogeninizing promotion.
  • a composition for promoting energy consumption and a composition for promoting energy consumption can be provided.
  • the present invention has the effect of promoting energy consumption in brown adipocytes through the above-mentioned PGC1 ⁇ and UCP1 gene expression promoting effects, and has anti-obesity, body fat reduction, fat metabolism promotion, fat burning promotion, heat production promotion and energy. It is possible to provide an oral composition in which each action of promoting consumption is effective. Further, according to the present invention, the expression of PGC1 ⁇ and UCP1 genes can be promoted, the energy consumption effect in brown adipocytes can be promoted, and the use of an effective composition containing tectrigenins and pinitol for obesity improvement, and A method for ameliorating obesity using tectrigenins and pinitol as active ingredients can be provided.
  • FIG. 1 is a graph showing the expression level of the PGC1 ⁇ gene in Examples and Comparative Examples.
  • FIG. 2 is a graph showing the expression level of the UCP1 gene in Examples and Comparative Examples.
  • the anti-obesity composition the body fat reducing composition, the fat metabolism promoting composition, the fat burning promoting composition, the heat production promoting composition, the energy consumption promoting composition and the oral composition of the present invention are described below. Are collectively referred to as "the composition of the present invention”.
  • Tectorigenins refer to tectrigenin, glycosides of tectrigenin and their derivatives. Tectorigenin is one of the flavonoids present in plants such as Iridaceae, and is represented by the molecular formula C 16 H 12 O 6 and is 5,7-Dihydroxy-3- (4-hydroxyphenyl) -6-methoxy-4 H-1-. It may also be called benzopyran-4-one or 6-Methoxy-5,7-dihydroxy-3- (4-hydroxyphenyl) -4H-1-benzopyran-4-one. In the present specification, the term tectrigenin is simply referred to as aglycone in the form of aglycone. The chemical formula of tectrigenin is as follows.
  • the tectrigenin glycoside in the present invention refers to the above-mentioned tectrigenin bound to one or more sugars selected from monosaccharides and / or sugar acid.
  • monosaccharide pentasaccharide and hexasaccharide are preferable, one or more selected from glucose, xylose, mannose, fructose, sorbose, galactose, apiose and rhamnose are more preferable, and one selected from glucose and xylose 1 Species or two species are particularly preferred.
  • sugar acid uronic acid is preferable, and glucuronic acid and galatic acid are particularly preferable.
  • these sugars and / or sugar acids are usually attached to the hydroxyl groups at the 4'and / or 7 positions of tectrigenin. In the present invention, those bonded to the hydroxyl group at the 7-position are preferable.
  • the number of sugars and / or sugar acids in the tectrigenin glycoside (also referred to as the number of sugar and / or sugar acid bonds) is, for example, 1 or more and 5 or less, preferably 1 or more and 4 or less. More than 3 pieces are particularly preferable.
  • the number of sugars and / or sugar acids refers to the total number of sugars and / or sugar acids.
  • n sugars are bound to tectrigenin may mean that a conjugate of n sugars is bound, and the total number of sugars bound to another part of tectrigenin is It may be n.
  • the glycoside contains sugar acid.
  • Examples of the derivative of tectrigenin or its glycoside include a compound in which one or more hydrogen atoms in tectrigenin or its glycoside are substituted with a substituent.
  • Examples of such a substituent include an amino group, a sulfonic acid group, an alkyl group having 1 or more and 6 or less carbon atoms, an alkoxy group having 1 or more and 4 or less carbon atoms, and the like.
  • the number of the above-mentioned substituents in the tectrigenins is preferably 8 or less, more preferably 4 or less, and most preferably 0.
  • the composition of the present invention may use only one of the above-mentioned tectrigenins, glycosides thereof and derivatives thereof as tectrigenins, or may use a mixture of two or more thereof.
  • the tectrigenins are tectrigenin and / or a glycoside thereof from the viewpoint of anti-obesity action.
  • the composition of the present invention contains tectrigenin as tectrigenins from the viewpoint of excellent effect of promoting energy consumption in brown adipocytes and easy availability.
  • the tectrigenins may be organic synthetic products or may be extracted from plants or the like.
  • Pinitol also called 3-O-methyl-D-kilo-inositol, is a type of inositol. Pinitol is contained in plants such as carob and clover. In the composition of the present invention, pinitol may be an organic synthetic product or may be extracted from a plant or the like.
  • the content ratio of tectrigenins and pinitol is in a specific range, it is preferable because the gene expression of PGC1 ⁇ and UCP1 is excellent and the energy consumption effect in brown adipocytes is higher.
  • the content ratio of tectrigenins and pinitol is preferably 1: 0.01 or more and 50 or less, preferably 1: 0.05 or more in terms of mass ratio of tectrigenins: pinitol. 30 or less is more preferable, and 1: 0.1 or more and 26 or less is particularly preferable.
  • the content ratio of tectrigenin to pinitol is preferably 1: 0.01 or more and 50 or less in terms of mass ratio, and particularly UCP1 gene expression. Since it is excellent in energy consumption action in brown adipocytes by promotion, it is particularly preferably more than 1: 0.5 and 30 or less, more preferably 1: 0.7 or more and 30 or less, and most preferably 1: 1 or more and 26 or less.
  • the amount of tectrigenins in the composition of the present invention can be measured by high performance liquid chromatography (HPLC method).
  • HPLC method high performance liquid chromatography
  • YMC-Pack ODS AM12S05-2546WT ( ⁇ 4.6 ⁇ 250 mm) manufactured by YMC Co., Ltd.
  • Mobile phase B volume ratio 35: 65: 0.1)
  • the column temperature can be 35 ° C.
  • the flow rate can be 1.0 ml / min.
  • the gradient conditions can be as shown in Table A below.
  • the amount of pinitol in the composition of the present invention can be measured by the HPLC method.
  • the composition of the present invention may contain other commonly used components as long as the effects of the present invention are not impaired.
  • Such ingredients include various excipients, binders, brighteners, lubricants, stabilizers, diluents, bulking agents, thickeners, emulsifiers, antioxidants, pH regulators, colorants, fragrances. , Additives and the like.
  • the content of other components can be appropriately selected depending on the form of the composition of the present invention and the like.
  • the composition of the present invention can be used for both oral and parenteral uses.
  • the parenteral agent include an agent administered by a method of directly administering to the stomach with a catheter or the like.
  • the composition of the present invention is used orally because the action of the present invention relating to the promotion of energy consumption can be easily obtained.
  • the form thereof includes, for example, tablets, capsules, powders, granules, liquids, granules, rods, plates, blocks, solids, rounds, and pastes. Examples thereof include agents, creams, capsules, gels, chewables, sticks and the like. Among these, the forms of tablets, capsules, powders, granules, and liquids are particularly preferable.
  • oral compositions used as tablets, capsules, powders, granules, liquids include supplements; food additives: bottled beverages filled in PET bottles, cans, bottles, etc .: water (hot water), Examples thereof include powdered beverages to be dissolved in milk, fruit juice and the like for drinking. These are preferable in that they are easy to eat and drink at the time of meals and can enhance the palatability.
  • food can be included as a food and drink composition.
  • foods include tea bags, various foods such as bread / confectionery and noodles, and cooked foods.
  • Breads and sweets include breads such as bread, sweet bread, French bread, British bread, muffins, steamed bread, donuts and waffles, butter cakes, sponge cakes, chiffon cakes, hot cakes and other cakes, chocolates and sherbets.
  • Cold cakes such as ice cream, jelly, cookies and the like.
  • noodles include udon noodles and somen noodles.
  • cooked products include soups such as curry, stew, miso soup, and vegetable soup, and seasonings based on them.
  • the composition of the present invention contains a total of 0.001% by mass or more and 40% by mass or less of pinitol and tectrigenins in its solid content in terms of promoting energy consumption in brown adipocytes and in daily life. It is preferable because it is easy to take it orally continuously, more preferably 0.005% by mass or more and 35% by mass or less, and particularly preferably 0.01% by mass or more and 30% by mass or less.
  • the solid content is the amount obtained by removing water from the composition.
  • the oral dose thereof is pinitol and tectrigenins in terms of promoting energy consumption in brown adipocytes and being easy to be orally ingested continuously in daily life.
  • it is preferably about 0.1 mg or more and 500 mg or less, and more preferably 0.5 mg or more and 300 mg or less per day for adults.
  • the single ingestion of the composition of the present invention is preferably the total amount of pinitol and tectrigenins, which is about 1 mg or more and 300 mg or less per day for an adult.
  • composition of the present invention examples include pharmaceuticals (including quasi-drugs), general foods, nutritionally functional foods, foods for specified health use whose efficacy has been approved by a predetermined institution, and functionality. So-called health foods such as labeled foods can be mentioned. Foods labeled with efficacy may be collectively referred to as "functional foods”.
  • the composition of the present invention promotes the expression of genes of a plurality of proteins related to energy consumption in brown adipocytes, thereby consuming energy in brown adipocytes and brown adipose tissue containing the same. It is possible to promote. Examples of such genes include the PGC1 ⁇ gene and the UCP1 gene.
  • PGC1 ⁇ (PPAR ⁇ coactivator 1 ⁇ ), which is a protein encoded by the PGC1 ⁇ gene, is a protein identified as a transcriptional coupling factor that activates transcription by the nuclear receptor PPAR ⁇ .
  • PGC1 ⁇ activates the transcription factor NRF (nuclear respiratory factor) 1 / NRF2, and NRF activates mitochondrial biosynthesis by promoting the transcription of TFAM (mitochondria transcription factor). It is known that mitochondria increase by promoting the gene expression of PGC1 ⁇ .
  • PGC1 ⁇ is a factor that binds the nuclear receptors of brown adipocytes and is involved in the promotion of UCP1 gene expression.
  • PGC1 ⁇ by promoting the gene expression of PGC1 ⁇ , an energy consumption promoting action can be expected through a mitochondrial increasing action and a UCP1 gene expression promoting action in brown adipocytes.
  • the gene for PGC1 ⁇ may also be described as Pgc1 ⁇ .
  • the UCP1 gene is a gene encoding molecular uncoupling protein 1 (UCP1), and may be described as Ucp1.
  • UCP1 gene is expressed specifically in the mitochondria of the brown adipocyte.
  • the UCP1 gene has the activity of uncoupling oxidative phosphorylation in mitochondria, and when it is activated, the energy generated by the oxidative decomposition of fatty acids and glucose is directly converted into heat without going to ATP synthesis and dissipated. Will be done.
  • the UCP1 gene By promoting the expression of the UCP1 gene, the consumption of fatty acids in brown adipocytes can be promoted to suppress or eliminate obesity.
  • the action of the present invention may promote the expression of only one of the PGC1 ⁇ gene and the UCP1 gene, or may promote the expression of both the PGC1 ⁇ gene and the UCP1 gene.
  • the composition of the present invention can be used for various purposes such as promoting fat burning, promoting heat production, promoting fat metabolism, reducing body fat, and promoting energy consumption, in addition to promoting the expression of PGC1 ⁇ gene and UCP1 gene. .. "For promoting fat burning” refers to promoting the action of brown adipocytes to convert fatty acids into heat. Promotion of heat production means, for example, promotion of heat production from neutral fat by brown adipocytes.
  • the fat metabolism promoting action refers to, for example, the action of qualitatively converting adipocytes and adipose tissue forming an obese state into small normal adipocytes, or the action of fatty acid metabolism by brown adipocytes.
  • the body fat reducing action means, for example, the action of reducing body fat by converting fatty acids into heat.
  • the anti-obesity use refers to an action of reducing or suppressing an increase in body fat by promoting the metabolism of fatty acids in brown adipose cells or brown adipose tissue, for example.
  • the term “energy consumption promotion” refers to promotion of the action of brown adipocytes to consume chemical energy such as fatty acids.
  • brown adipocytes include the liver, muscles, the vicinity of the clavicle, the chest (around the chest), the shoulders (the scapula and its surroundings), and the like.
  • composition of the present invention may be a product that can be distinguished from other products in that it is used for promoting adipose decomposition, anti-obesity, and dieting, and for example, it has a function of promoting adipose decomposition.
  • the display is for those who are concerned about obesity, those who are concerned about the abdominal circumference, those who are concerned about weight, those who are concerned about abdominal fat (visceral fat and subcutaneous fat, etc.), etc.
  • the differentiation-inducing medium containing the test substance was prepared as follows. That is, each test substance was dissolved in DMSO, diluted with a differentiation-inducing medium, adjusted to a final DMSO concentration of 0.5 vol%, and sterilized by a filter. After sterilization, tectrigenin and pinitol were diluted to the concentrations shown in Table 1 below using a differentiation-inducing medium containing 0.5 vol% DMSO.
  • the differentiation maintenance medium containing the test substance was prepared as follows. That is, each test substance was dissolved in DMSO, diluted with a differentiation maintenance medium, prepared so that the final concentration of DMSO was 0.5 vol%, and sterilized by a filter. After sterilization, tectrigenin and pinitol were diluted to the concentrations shown in Table 1 below using a differentiation maintenance medium containing 0.5 vol% DMSO.
  • a 24-well plate coated with rat brown adipose precursor cells (manufactured by Cosmo Bio) was seeded at 500 ⁇ l / well using a growth medium so as to have 3.0 ⁇ 10 4 cells / well, and 37 ° C. Incubate in a 5 (vol / vol)% CO 2 incubator until the cell density reached about 90%.
  • FIG. 1 shows the relative values of the mRNA gene expression levels of PGC1 ⁇ according to Example 1 and Comparative Examples 1 and 2 when the value of Comparative Example 1 is 1.
  • UCP1 gene expression level [Examples 2 to 4 and Comparative Examples 3 and 4]
  • a UCP1 gene primer (manufactured by QIAGEN) was used instead of Pgc1 ⁇ . Further, as the test substance, the test substance having the composition shown in Table 2 below was used. The concentration of the test substance in the differentiation-inducing medium and the differentiation-maintaining medium was 50 ⁇ M. Except for this point, the expression level of the mRNA gene of UCP1 was measured in the same manner as in [Example 1 and Comparative Examples 1 and 2].
  • FIG. 2 shows the relative values of the expression levels of the UCP1 mRNA genes according to Examples 2 to 4 and Comparative Examples 3 and 4 when the value of Comparative Example 3 is 1.
  • a granule consisting of the following ingredients (3000 mg per packet) was manufactured.
  • An excellent anti-obesity effect can be obtained by ingesting the obtained granules twice a day by suspending one packet in water.
  • a granule consisting of the following ingredients (2000 mg per packet) was manufactured.
  • An excellent anti-obesity effect can be obtained by suspending the obtained granules three times a day in hot water and ingesting one packet at a time.
  • a tablet (200 mg per tablet) consisting of the following ingredients was manufactured.
  • An excellent anti-obesity effect can be obtained by ingesting 4 tablets of the obtained tablets twice a day.
  • a tablet (300 mg per tablet) consisting of the following ingredients was manufactured.
  • An excellent anti-obesity effect can be obtained by ingesting 5 tablets of the obtained tablets once a day.
  • a capsule containing the following ingredients (300 mg per capsule) was manufactured.
  • An excellent anti-obesity effect can be obtained by ingesting 2 capsules of the obtained capsule twice a day.
  • composition of the present invention can be expected to have a high anti-obesity effect, it is highly industrially useful.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention aborde le problème de la fourniture d'une composition anti-obésité et d'une composition pour administration orale : qui peuvent favoriser l'expression génique de protéines telles que PGC1α et UCP1 qui sont associées aux adipocytes bruns ou à leur action de consommation d'énergie ; et qui ont pour effet de favoriser l'action de consommation d'énergie des adipocytes bruns.　Cette composition contient de la tectorigénine et du pinitol. Ladite tectorigénine est de préférence de la tectorigénine. Cette composition peut être utilisée de manière appropriée comme composition anti-obésité et comme composition pour administration orale.
PCT/JP2021/003384 2020-06-18 2021-01-29 Composition anti-obésité et composition pour administration orale WO2021255979A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US17/800,584 US20230123101A1 (en) 2020-06-18 2021-01-29 Anti-obesity composition and composition for oral administration
JP2021508004A JP6903367B1 (ja) 2020-06-18 2021-01-29 抗肥満用組成物及び経口用組成物
CN202180012480.1A CN115052591A (zh) 2020-06-18 2021-01-29 抗肥胖用组合物及经口用组合物
KR1020227026940A KR20230023604A (ko) 2020-06-18 2021-01-29 항비만용 조성물 및 경구용 조성물

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020105308 2020-06-18
JP2020-105308 2020-06-18

Publications (1)

Publication Number Publication Date
WO2021255979A1 true WO2021255979A1 (fr) 2021-12-23

Family

ID=79241779

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/003384 WO2021255979A1 (fr) 2020-06-18 2021-01-29 Composition anti-obésité et composition pour administration orale

Country Status (2)

Country Link
JP (1) JP2022000011A (fr)
WO (1) WO2021255979A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009196931A (ja) * 2008-02-21 2009-09-03 Kobe Univ 抗肥満剤およびそれを用いた飲食品
JP2017171654A (ja) * 2016-03-16 2017-09-28 株式会社東洋新薬 組織分化促進用組成物、肝機能改善用組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009196931A (ja) * 2008-02-21 2009-09-03 Kobe Univ 抗肥満剤およびそれを用いた飲食品
JP2017171654A (ja) * 2016-03-16 2017-09-28 株式会社東洋新薬 組織分化促進用組成物、肝機能改善用組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOI MYUNG-SOOK, LEE MI-KYUNG, JUNG UN JU, KIM HYE-JIN, DO GEOYNG-MIN, PARK YONG BOK, JEON SEON-MIN: "Metabolic response of soy pinitol on lipid-lowering, antioxidant and hepatoprotective action in hamsters fed-high fat and high cholesterol diet", MOLECULAR NUTRITION & FOOD RESEARCH, WILEY - VCH VERLAG, WEINHEIM, DE, vol. 53, no. 6, 1 June 2009 (2009-06-01), DE , pages 751 - 759, XP055891111, ISSN: 1613-4125, DOI: 10.1002/mnfr.200800241 *
FUJIKI, KOHEI ET AL.: "The Strong Evidence of Pueraria Flower Extract", FOOD STYLE, vol. 22, no. 8, 2018, pages 88 - 91, ISSN: 1343-9502 *

Also Published As

Publication number Publication date
JP2022000011A (ja) 2022-01-04

Similar Documents

Publication Publication Date Title
EP2754444B1 (fr) Composition pour améliorer un paramètre du métabolisme in vivo
KR101692033B1 (ko) Ｄ-싸이코스를 유효성분으로 함유하는 지질 관련 대사성 질환의 예방 또는 치료용 조성물
EP2218342A2 (fr) Nouvelles compositions nutraceutiques et utilisations
JP7304655B2 (ja) 組織分化促進用組成物、肝機能改善用組成物
KR20190099481A (ko) 이소잔토휴몰을 함유하는 지질 대사 촉진용 조성물
JP5175442B2 (ja) ヤーコン由来の抗ガン剤
JP5619752B2 (ja) パンドラチン誘導体またはボエセンベルギアパンドラタ抽出物の新規な用途
WO2021255979A1 (fr) Composition anti-obésité et composition pour administration orale
JP6903367B1 (ja) 抗肥満用組成物及び経口用組成物
EP3560340A1 (fr) Composition favorisant l'excrétion de lipides végétaux et comprenant de l'allulose
JP6391959B2 (ja) 非アルコール性脂肪性肝炎の改善剤および改善用栄養組成物
EP2939672B1 (fr) Agent favorisant la production d'igf-1
KR20170027272A (ko) Ｄ-싸이코스를 유효성분으로 함유하는 지질 관련 대사성 질환의 예방 또는 치료용 조성물
KR20130112980A (ko) 크레이스토카릭스 오페르쿠라투스 추출물 및 이로부터 분리된 화합물을 유효성분으로 포함하는 동맥경화증의 예방 또는 치료용 조성물
KR20140093573A (ko) 디하이드로진저론을 함유하는 비만 치료 또는 예방용 조성물
JP7239135B2 (ja) α－グルコシダーゼ活性阻害剤および血糖値上昇抑制剤
WO2024071138A1 (fr) Composition améliorant la fonction mitochondriale
JP7156639B2 (ja) レスベラトロール誘導体の新規用途
JP2023038107A (ja) 脂質合成抑制剤及びこれを含む飲食品、脂質合成抑制用加工食品並びに発現抑制剤
JP2013006809A (ja) 新規イソフラボン化合物
JP2015059102A (ja) 筋肉増量剤及び運動併用時の筋肉増量剤
JP2013091616A (ja) 上皮型ナトリウムチャネル発現抑制剤
JP2015042630A (ja) 運動併用時の早期血糖低下剤

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2021508004

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21825752

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21825752

Country of ref document: EP

Kind code of ref document: A1